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‘Of concern is the WHO Region of the Amer-
icas, where incidence is estimated to be slowly 
increasing after many years of decline, owing 
to an upward trend in Brazil during 2016–
2019.’—2020 Global TB report.
On the 24 March, we will commemo-
rate the World TB Day. Despite important 
achievements on tuberculosis (TB) control 
summarised in the 2020 WHO Global TB 
report,1 the above quotation referring to the 
WHO Region of the Americas is concerning. 
In contrast with global decreases in TB inci-
dence rates over the past decade, in 2019, the 
Region of the Americas has taken a step back-
wards and the TB incidence rate has shown 
an unexpected upturn in recent years (online 
supplemental efigure-1 in the supplemental 
file).
The Region of the Americas comprises 
46 countries and territories and Brazil and 
Peru are among the WHO high- TB burden 
countries. To illustrate the recent increase 
in TB incidence in the region, we selected 
12 countries from Latin America (Argentina, 
Brazil, Chile, Colombia, Ecuador, El Salvador, 
Mexico, Panama, Paraguay, Peru, Uruguay 
and Venezuela), which account for approxi-
mately 80% of the total estimated TB cases in 
the region. Using data from WHO TB data-
bases (exported on 22 October 2020), we 
show that, between 2014 and 2019, the esti-
mated TB incidence rate increased from 38.4 
to 41.7 per 100 000 (8.6% relative increase) 
and the estimated number of incident cases 
increased from 202 290 to 230 100 (27 810 
more cases, 13.8% relative increase) for these 
12 countries (figure 1, for the same data in 
separated panels by each country, please see 
online supplemental eFigure-2 in the supple-
mental file).
This worrying scenario, in the context of 
elimination strategies in other continents, 
should not go unnoticed without clear action. 
Several factors may play a role in this resur-
gence. In recent years, Latin America is 
facing economic, social and political crises, 
increasing population vulnerabilities to 
acquire and progress to TB disease in several 
ways. TB is, unfortunately, a marker of social 
inequity and the paradigm of poverty- related 
diseases; with the most vulnerable popula-
tions typically enduring the highest burden.1 
In Latin America, poverty has decreased from 
230 million (45.4%) to 164 million persons 
(27.8%) between 2002 and 2014. However, 
since 2015, poverty has begun to increase, 
reaching 191 million (30.8%) in 2019, an 
additional of 27 million persons returning to 
poverty compared with 2014.2 Venezuela and 
Brazil were the main drivers of these increases. 
In addition, other indicators of vulnera-
bility have also surged: more than 4 million 
residents from Venezuela have migrated to 
neighbouring countries since 2014.3 Further-
more, the number of persons experiencing 
homelessness has doubled from 2012 to 2019 
in Brazil.4 Finally, incarcerated prison popula-
tions have increased by 206% across Central 
and South America between 2000 and 2018.5 6
Venezuela has seen the most dramatic 
upward trend in TB incidence, almost 
doubling from 26.6/100 000 in 2014 to 
45.6/100 000 in 2019 (figure 1). In Argen-
tina, incidence rates declined from 38.0/100 
000 in 2000 to 20.5/100 000 in 2010, but the 
country’s progress has receded and experi-
enced a 41.5% relative increase from 2010 
to 2019 (29.0/100 000 on 2019). Uruguay 
also shows a continuous increase in TB inci-
dence rate since 2007. In Brazil, the estimated 
incidence increased from 42.9/100 000 in 
2014 to 45.5/100 000 in 2019 (6·1% relative 
increase), representing approximately 9000 
additional incident cases.
National Tuberculosis Programmes, the 
Pan American Health Organization, and 
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have made a huge effort on TB control in Latin America. 
In recent years, several countries have become ineli-
gible for certain international donors (eg, Global Fund), 
partially because of their socioeconomic development, 
but also because of recent TB control successes. There-
fore, retaining investments in TB control in the region 
is critical.
A first step to mitigate the health impact of this 
recent trend is to disentangle its main drivers (table 1). 
It is likely this resurgence is due to multiple factors 
and should be within the framework of already known 
TB drivers.1 Researchers, academics and National TB 
programmes should take advantage of TB morbidity and 
mortality surveillance to describe where recent increases 
Figure 1 Estimated incidence rate, case notification rate and estimated incident cases of tuberculosis for 12 countries in Latin 
America between 2000 and 2019. Data generated from the tuberculosis WHO most updated database, exported on 22 October 
2020. *Venezuela stands for Bolivarian Republic of Venezuela.
Table 1 A proposed framework for initial areas of research to understand and mitigate the recent increase of tuberculosis in 
Latin America
Area Questions Actors
Theoretical What are the actions and pathways 
responsible for the recent increase of 
TB in Latin America?
 ► To establish theoretical models aiming to explain the phenomenon, 
describe the complex interactions and support the analysis of causal 
research questions
Descriptive When, where and how much is 
occurring the recent increase in TB 
incidence?
 ► To describe the time series of TB cases/incidence stratified by 
demographic features such as age and sex, regions and groups of interest
 ► To quantify the trend of the increased incidence in TB in relative (ie, 
growth rate) and absolute measures
Epidemiology What are the main drivers of recent 
increase in TB incidence?
 ► To evaluate factors associated with the recent increase in TB using 
ecological data
 ► To quantify the contribution of factors on the relative increase of TB 
incidence using individual population data
 ► To estimate the population attributable fraction (PAF) of each factor 
associated with the TB increase and the combined risk factors 
(intersectional approach)
Modelling In a complex scenario, what 
parameters could explain and 
mitigate the recent increase in TB 
incidence?
 ► To account for the several players and changes in the region, accounting 
for its heterogeneity, to explain the observed phenomena
 ► To simulate scenarios of potential interventions to mitigate the recent 
increase and return to the phase of decreasing incidence
 ► To evaluate cost- effective interventions in the short term and long term 





Does the intervention X could reduce 
incidence of TB in the region?
 ► To evaluate better strategies to implement and optimise already known 
interventions to reduce incidence of TB, taking account the particularities 
of Latin America
 ► To perform randomised interventions based on the main drivers aiming 
to reduce the incidence of TB, focusing on prevention of transmission, 
development of disease after infection and treatment
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are occurring in terms of key demographic variables (eg, 
age and sex), geographical location within each country,7 
and stratified by main groups of interest, such as those 
with HIV infection and prisoners.5–8 Additionally, studies 
with individual data, allowing for robust estimates of 
drivers on TB incidence in the region are needed. Other 
actions in the region should be considered because of 
their direct impact on improved diagnosis and notifica-
tion of cases, such as roll out of platforms for molecular 
testing (GeneXpert), implementation of active contact 
tracing strategies and improved surveillance systems 
(quality and coverage).8–10 Additionally, research and 
surveillance should aim to characterise TB transmission 
dynamics using molecular tools. The introduction of new 
lineages or resurgence of new strains in the region could 
be associated with increased transmission, while going 
unnoticed.11 Finally, the use of modelling techniques may 
incorporate data on identified drivers associated with 
the observed upward trend in TB notifications in several 
Latin American countries, providing a better under-
standing and shedding light on mitigation opportunities.
The health and social impact of increasing TB burden 
in the region may be vast. Moreover, this worrying trend 
may by amplified by the impact of the current COVID-19 
pandemic, which is expected to increase TB burden in 
the upcoming future. Irrespective of the negative impact 
of the COVID-19 pandemic in regional control efforts, 
TB is associated with considerable health burden not 
only on deaths and years of life lost, but also on comor-
bidities and subsequent quality of life during and after 
the TB episode.1 12 13 Increased health demand caused 
by post- TB lung disease is expected.13 Additionally, TB 
patients can experience exacerbation of previous chronic 
diseases, such as diabetes and chronic respiratory disor-
ders. In this context, previous chronic diseases and recent 
sequelae from TB might have even worse treatment and 
control if we consider the catastrophic cost affecting 
patients and relatives that usually occurs during and after 
TB treatment. This scenario associated with the barriers 
to achieve universal health coverage in the region,14 can 
be amplified by the ongoing socioeconomic crisis and 
implementation of austerity measures in some countries 
of Latin America.15
The need to act on a multifaceted platform to tackle 
the resurgence of TB in Latin America is now urgent. We 
expect additional challenges for health systems coping 
with the ongoing COVID-19 pandemic and its sequelae, 
which are likely to continue to impact TB care. TB 
control in the Americas is likely to worsen in upcoming 
years if remedial, coordinated actions are not urgently 
implemented to reverse these trends. Otherwise, years of 
thorough efforts in TB control will be lost.
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